Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices.

Endothelial cell seeding, a promising method to improve the performance of small-diameter vascular grafts, requires a suitable substrate, e.g. crosslinked collagen. In addition, the growth of seeded endothelial cells can be improved by local release of a heparin-binding protein, basic fibroblast growth factor (bFGF). In this study, the influence of immobilization of heparin to collagen, crosslinked using N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) in combination with N-hydroxysuccinimide (NHS), on the binding and release of bFGF was determined. Heparin was immobilized also using EDC and NHS. Furthermore, the effects of the release of bFGF from (heparinized) EDC/NHS-crosslinked collagen on the proliferation of seeded endothelial cells was studied in vitro. Immobilization of increasing amounts of heparin to EDC/NHS-crosslinked collagen (containing 14 free epsilon-amino groups per 1000 amino acid residues, E/N14C) resulted in binding of increasing amounts of bFGF to the material. Maximal bFGF binding was observed for E/N14C containing 20-30 mg heparin immobilized per gram of collagen which was obtained using a molar ratio of EDC to heparin-carboxylic acid groups of 0.4 for heparin immobilization (E/N14C-H(0.4)). Up to concentrations of 320 ng bFGF/ml, 10% of the added bFGF bound to E/N14C, while binding of bFGF to E/N14C-H(0.4) was 22%. The initial release rate of bFGF bound to E/N14C was much higher compared to bFGF bound to E/N14C-H(0.4): respectively, 30 vs. 2% in the first 6 h. After 10 days, the bFGF release from E/N14C and E/N14C-H(0.4) amounted to 83 vs. 42%, respectively. Binding of increasing amounts of bFGF resulted in increased growth of human umbilical vein endothelial cells (HUVECs) seeded on both E/N14C and E/N14C-H(0.4). Nevertheless, after 6 and 10 days of proliferation cell numbers on E/N14C-H(0.4) where higher than cell numbers on E/N14C, irrespective of the bFGF concentration used for loading of the matrix. It is concluded that heparinized, EDC/NHS-crosslinked collagen is a good synthetic vascular graft coating for in vivo endothelial cell seeding.

[1]  D. Gospodarowicz,et al.  Brain-derived fibroblast growth factor: a study of its inactivation. , 1983, Life sciences.

[2]  S. Sprang,et al.  Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Roger L. Lundblad,et al.  Chemical Reagents for Protein Modification , 1984 .

[4]  W. Moore,et al.  Development of a [ldquo ]leak-proof,[rdquo ] knitted Dacron vascular prosthesis , 1986 .

[5]  Y. Wilson,et al.  Preferential use of vein for above-knee femoropopliteal grafts. , 1995, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[6]  B. Matthews,et al.  Three-dimensional structure of human basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. W. Kim,et al.  Macromolecular release from collagen monolithic devices. , 1990, Journal of biomedical materials research.

[8]  D. Gospodarowicz,et al.  Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.

[9]  E Wolner,et al.  Toxic effects of aldehydes released from fixed pericardium on bovine aortic endothelial cells. , 1989, Journal of biomedical materials research.

[10]  D. Rifkin,et al.  Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan , 1989, Journal of cellular physiology.

[11]  J. Folkman,et al.  Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. , 1989, Biochemistry.

[12]  J. Gallagher.  Heparan sulphates as membrane receptors for the fibroblast growth factors. , 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[13]  K. Holme,et al.  Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor. , 1994, Glycobiology.

[14]  T. Maciag,et al.  The heparin-binding (fibroblast) growth factor family of proteins. , 1989, Annual review of biochemistry.

[15]  M A Markwell,et al.  A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. , 1982, Analytical biochemistry.

[16]  P. Dell’Era,et al.  Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. , 1994, Biochemical and biophysical research communications.

[17]  W. Moore,et al.  Development of a "leak-proof," knitted Dacron vascular prosthesis. , 1986, Journal of vascular surgery.

[18]  D. Gospodarowicz,et al.  Extracellular matrix and control of proliferation of vascular endothelial cells. , 1980, The Journal of clinical investigation.

[19]  J. Feijen,et al.  Glutaraldehyde as a crosslinking agent for collagen-based biomaterials , 1995 .

[20]  J. Bancroft,et al.  Theory and Practice of Histological Techniques , 1990 .

[21]  A. Baird.  Potential mechanisms regulating the extracellular activities of basic fibroblast growth factor (FGF‐2) , 1994, Molecular reproduction and development.

[22]  E. Khor,et al.  Validation of the shrinkage temperature of animal tissue for bioprosthetic heart valve application by differential scanning calorimetry. , 1995, Biomaterials.

[23]  W. Abbott.  Prosthetic above-knee femoral-popliteal bypass: indications and choice of graft. , 1997, Seminars in vascular surgery.

[24]  S. Gutschi,et al.  [Femoropopliteal vascular replacement: vein, ePTFE or ovine collagen?]. , 1996, Zentralblatt fur Chirurgie.

[25]  A. Bantjes,et al.  N-Hydroxysuccinimide-activated glycine-sepharose , 1993 .

[26]  T. van Vroonhoven,et al.  Polytetrafluoroethylene versus human umbilical vein in above-knee femoropopliteal bypass: six-year results of a randomized clinical trial. , 1992, Journal of vascular surgery.

[27]  P. Groot,et al.  Von Willebrand Factor in Cultured Human Vascular Endothelial Cells from Adult and Umbilical Cord Arteries and Veins , 1986, Thrombosis and Haemostasis.

[28]  J. Ménard,et al.  Femoropopliteal Bypass: In Situ or Reversed Vein Grafts? Ten-Year Results of a Randomized Prospective Study , 1997, Annals of vascular surgery.

[29]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[30]  J. Feijen,et al.  Relations between in vitro cytotoxicity and crosslinked dermal sheep collagens. , 1992, Journal of biomedical materials research.

[31]  P. Kreienberg,et al.  The performance of femoropopliteal bypasses using polytetrafluoroethylene above the knee versus autogenous vein below the knee. , 1997, American journal of surgery.

[32]  Fibroblast growth factors. , 1989, British medical bulletin.

[33]  L. Bengtsson,et al.  Lining of viable and nonviable allogeneic and xenogeneic cardiovascular tissue with cultured adult human venous endothelium. , 1993, The Journal of thoracic and cardiovascular surgery.

[34]  J. Feijen,et al.  Adhesion of endothelial cells and adsorption of serum proteins on gas plasma-treated polytetrafluoroethylene. , 1991, Biomaterials.

[35]  G. L’italien,et al.  Femoropopliteal reconstruction with knitted, nonvelour Dacron versus expanded polytetrafluoroethylene. , 1992, Journal of vascular surgery.

[36]  T. Miyata,et al.  Collagen-induced platelet aggregation and release. I Effects of side-chain modifications and role of arginyl residues. , 1978, Biochimica et biophysica acta.

[37]  M E Nimni,et al.  Biochemical changes and cytotoxicity associated with the degradation of polymeric glutaraldehyde derived crosslinks. , 1990, Journal of biomedical materials research.

[38]  J. C. Smith,et al.  Femoropopliteal bypass with externally supported knitted Dacron grafts: a follow-up of 200 grafts for one to twelve years. , 1994, Journal of vascular surgery.

[39]  J. Feijen,et al.  Proliferation of endothelial cells on surface-immobilized albumin-heparin conjugate loaded with basic fibroblast growth factor. , 1999, Journal of biomedical materials research.

[40]  G. Giménez-Gallego,et al.  Expression in Escherichia coli of a Chemically Synthesized Gene for Biologically Active Bovine Acidic Fibroblast Growth Factor , 1987, Bio/Technology.

[41]  M E Nimni,et al.  Toxic reactions evoked by glutaraldehyde-fixed pericardium and cardiac valve tissue bioprosthesis. , 1984, Journal of biomedical materials research.

[42]  J. Feijen,et al.  Design of a new type of coating for the controlled release of heparin , 1997 .

[43]  C. Doillon,et al.  Heparin-fibroblast growth factor-fibrin complex: in vitro and in vivo applications to collagen-based materials. , 1994, Biomaterials.

[44]  J. Feijen,et al.  Calcification of subcutaneously implanted collagens in relation to cytotoxicity, cellular interactions and crosslinking , 1995 .

[45]  C. L. Borders,et al.  Stability of water-soluble carbodiimides in aqueous solution. , 1990, Analytical biochemistry.

[46]  T. Arakawa,et al.  Stoichiometry of heparin binding to basic fibroblast growth factor. , 1994, Archives of biochemistry and biophysics.

[47]  L. Berry,et al.  Tritiation of commercial heparins by reaction with NaB3H4: chemical analysis and biological properties of the product. , 1980, Analytical biochemistry.

[48]  G. M. Fox,et al.  Binding of heparin to basic fibroblast growth factor induces a conformational change. , 1992, Archives of biochemistry and biophysics.